AS Insights launch new report
Insulin State of the Science and Strategic Opportunities
The world market for insulin was valued at
US$3.5 billion in 2001. Europe accounted for 40% of the market and the US
for 38%. Human insulin is an epidemiology driven market and
epidemiologically speaking diabetes is on the rise.
Due to increased knowledge regarding
improved therapy with insulin, physicians are steadily switching NIDDM to
human insulin, thus increasing the total market. Doctor's awareness of the
disease and its means of diagnosis are improving which is increasing the
patient pool.
Although the insulin market has been stable
for a long time due to sheer size and fortification of the two leading
producers and the high barriers to entry, this is about to change soon
with the introduction of new delivery systems and new players on the world
stage. Of particular interest is the eminent launch of inhalation insulin
products by Pfizer, Aventis and Novo Nordisk
Human Insulin, State-of-the-Science &
Strategic Opportunities is a strategic business report that assesses both
the technology status and the competitive landscape of the world insulin
market. The report examines both the US and the European markets in
detail, profiles leading products and companies and offers revenue
forecasts to the year 2007. The report assesses the market attractiveness
and potential and evaluates the impact of new product launch on the
market.
Report Code: 0212AS1B
Report Price:
US$485 Hard Copy (including shipping &
handling) US$285 PDF Format (delivered by email)
Date Published: November 2002
Number of Pages: 28
To order - click
here!
